TWI612966B - 南洋山蘇水萃物的用途 - Google Patents
南洋山蘇水萃物的用途 Download PDFInfo
- Publication number
- TWI612966B TWI612966B TW106118699A TW106118699A TWI612966B TW I612966 B TWI612966 B TW I612966B TW 106118699 A TW106118699 A TW 106118699A TW 106118699 A TW106118699 A TW 106118699A TW I612966 B TWI612966 B TW I612966B
- Authority
- TW
- Taiwan
- Prior art keywords
- extract
- nanyangshan
- nanyangshan sushui
- sushui extract
- nanyangshansu
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 37
- 241001312267 Asplenium australasicum Species 0.000 title description 2
- 206010061218 Inflammation Diseases 0.000 claims abstract description 18
- 230000004054 inflammatory process Effects 0.000 claims abstract description 18
- 208000015181 infectious disease Diseases 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 8
- -1 IL-1β Proteins 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 241001453169 Asplenium Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010034344 Peptic ulcer haemorrhage Diseases 0.000 description 1
- 206010034354 Peptic ulcer perforation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Plant Substances (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
Abstract
一種南洋山蘇水萃物的用途,係用以製備抑制革蘭氏陰性菌感染所造成之發炎的藥物,其中,該南洋山蘇水萃物係以水作為一萃取溶劑,於115~125℃之溫度、0.35~0.5Kg/cm2G之壓力下萃取一南洋山蘇樣品1.5~3小時所獲得。
Description
本發明係關於一種南洋山蘇水萃物的用途,特別關於一種南洋山蘇水萃物應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物的用途。
脂多糖(lipopolysaccharide)又稱作內毒素(endotoxin),是革蘭氏陰性菌(Gram-negative bacteria)外膜的主要組成部分,提供細菌以結構的完整性(structural integrity),並保護細菌膜受某些化學物質的攻擊。當動物體遭受革蘭氏陰性菌感染時,其巨噬細胞(macrophage)會釋放出TNF-α、IL-1β、IL-6等促發炎細胞激素(proinflammatory cytokine),這些細胞激素會提升血管通透性(vascular permeability),導致熱(fever)、痛(pain)、腫(swelling)等發炎反應,並刺激活化巨噬細胞分泌更多促進發炎的細胞激素而造成發炎反應。
一般而言,發炎是身體為移除有害病原體及促進組織修復的保護措施,但是長期發炎將造成人體不適,甚或惡化而破壞生理組織導致壞死;因此發炎反應一旦發生,應密切注意並避免惡化。
吲哚美辛(indomethacin)為一種習用抑制革蘭氏陰性菌感染所造成之發炎的的藥物,主要用以抑制發炎反應所造成的熱、痛、腫等現象,惟其卻可能導致消化性潰瘍(peptic ulcers)而造成嚴重的出血(bleeding)或穿孔(perforated peptic ulcer),是以,確實仍有必要發展新
的抑制革蘭氏陰性菌感染所造成之發炎的藥物。
為解決上述問題,本發明提供一種南洋山蘇水萃物的用途,係將萃取自南洋山蘇之活性成分,應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物者。
本發明之南洋山蘇水萃物的用途,係應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物,其中,該南洋山蘇水萃物係水於115~125℃之溫度、0.35~0.5Kg/cm2G之壓力下萃取1.5~3小時所獲得;如此藉由萃取自南洋山蘇之活性成分,可以抑制脂多糖所誘導之TNF-α、IL-1β、IL-6等促發炎細胞激素的生成,藉此降低發炎反應的發生,因而可以應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物,為本發明之功效。
第1圖:投予本發明南洋山蘇水萃物對RAW264.7細胞株之存活率的影響結果柱狀圖。
第2a圖:投予本發明南洋山蘇水萃物對RAW264.7細胞株之TNF-α RNA生成量的影響結果柱狀圖。
第2b圖:投予本發明南洋山蘇水萃物對RAW264.7細胞株之IL-1β RNA生成量的影響結果柱狀圖。
第2c圖:投予本發明南洋山蘇水萃物對RAW264.7細胞株之IL-6 RNA生成量的影響結果柱狀圖。
第3a圖:投予本發明南洋山蘇水萃物對RAW264.7細胞株之TNF-α蛋白質分泌量的影響結果柱狀圖。
第3b圖:投予本發明南洋山蘇水萃物對RAW264.7細胞株之IL-1β
蛋白質分泌量的影響結果柱狀圖。
第3c圖:投予本發明南洋山蘇水萃物對RAW264.7細胞株之IL-6蛋白質分泌量的影響結果柱狀圖。
為讓本發明之上述及其他目的、特徵及優點能更明顯易懂,下文特舉本發明之較佳實施例,並配合所附圖式,作詳細說明如下:本發明所述之「南洋山蘇(Asplenium australasicum(J.Sm.)Hook.)」,係指鐵角蕨科(Aspleniaceae)鐵角蕨屬(Asplenium)的植物,其新生嫩葉(young emerging frond)常被作為食用菜葉。
本發明之南洋山蘇水萃物,係可以抑制脂多糖所誘導之TNF-α、IL-1β、IL-6等促發炎細胞激素的生成,藉此降低發炎反應的發生,因而可以應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物,該南洋山蘇水萃物與醫藥學上可以接受之載劑或賦形劑組合形成一醫藥組合物,其中,該南洋山蘇水萃物係可以製備成任何方便食用之型式,如錠劑、膠囊、粉劑、粒劑或液劑等,或者將該南洋山蘇水萃物與其他食品或飲料組合,以適於食用之樣態供生物體以口服方式服用。
其中,該南洋山蘇水萃物較佳係可以藉由一包含以下步驟之方法所製得:提供一南洋山蘇樣品;以水作為一萃取溶劑萃取該南洋山蘇樣品;及將南洋山蘇粗萃液進行濃縮,以獲得該南洋山蘇水萃物。
詳而言之,該南洋山蘇樣品係可以為南洋山蘇之成熟老葉(三年以上,背面分布孢子),較佳係可以預先將該南洋山蘇樣品於110~120℃之溫度下進行乾燥(將100克南洋山蘇樣品乾燥至20克),得到一南洋山蘇乾燥物;此外,該南洋山蘇樣品亦可以預先碎成粉粒(粒徑約為1~2mm),以增加該南洋山蘇樣品與該萃取溶劑之接觸表面積,藉此提升後續萃取之萃取效率。
舉例而言,每4.8kg之南洋山蘇樣品係能夠混合該萃取溶劑,使二者總體積達80L,並於115~125℃之溫度、0.35~0.5Kg/cm2G之壓力下進行萃取1.5~3小時,上述萃取亦可以重複數次,使該南洋山蘇樣品所富含之活性成分可以完整溶出於該萃取溶劑,此為本發明所屬技術領域中具有通常知識者所廣泛應用,在此不加以贅述。
前述之南洋山蘇粗萃液可以經過減壓濃縮及冷凍乾燥,以獲得該南洋山蘇水萃物,藉由此一程序,係可以使該南洋山蘇水萃物之活性成分更加濃縮,是以僅需使用少量之該南洋山蘇水萃物即可以發揮最佳療效。
為證實本發明之南洋山蘇水萃物係可以抑制TNF-α、IL-1β、IL-6等細胞激素的生成,遂進行以下試驗。
(A)南洋山蘇水萃物對細胞存活率的影響
請參照第1表所示,本試驗係分別以不同濃度之南洋山蘇水萃物處理RAW264.7細胞株1小時後,加入LPS(1μg/mL)處理24小時,續以CellTiter 96 AQueous One Solution Cell Proliferation Assay之方式偵測各組細胞的存活率,其結果如第1圖所示。
請參照第1圖所示,濃度為50μL/mL以下的南洋山蘇水萃物對RAW264.7細胞株不具細胞毒性(第A1~A4組)。
(B)南洋山蘇水萃物對促發炎細胞激素生成量的影響
請參照第2表所示,本試驗係分別以不同濃度之南洋山蘇水萃物處理RAW264.7細胞株1小時後,加入LPS(1μg/mL)處理24小時,續收取各組細胞的總RNA,進行反轉錄反應後,利用對應的引子對偵測其中的TNF-α、IL-1β、IL-6等促發炎細胞激素的RNA含量,其結果分別如第2a、2b、2c圖所示。
請參照第2a~2c圖所示,南洋山蘇水萃物的處理均能夠抑制TNF-α、IL-1β、IL-6等促發炎細胞激素的RNA表現,且抑制效果具有劑量依賴性。
(C)南洋山蘇水萃物對促發炎細胞激素分泌量的影響
請參照第3表所示,本試驗係分別以不同濃度之南洋山蘇水萃物處理RAW264.7細胞株1小時後,加入LPS(1μg/mL)處理24小時,
續收取各組的細胞上清液,以ELISA之方式偵測其中的TNF-α、IL-1β、IL-6等促發炎細胞激素的蛋白質含量,其結果分別如第3a、3b、3c圖所示。
請參照第3a~3c圖所示,南洋山蘇水萃物的處理均能夠抑制TNF-α、IL-1β、IL-6等促發炎細胞激素的蛋白質分泌量,且抑制效果具有劑量依賴性。
綜合上述,本發明之南洋山蘇水萃物的用途係藉由萃取自南洋山蘇之活性成分,可以抑制脂多糖所誘導之TNF-α、IL-1β、IL-6等促發炎細胞激素的生成,藉此降低發炎反應的發生,因而可以應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物,為本發明之功效。
雖然本發明已利用上述較佳實施例揭示,然其並非用以限定本發明,任何熟習此技藝者在不脫離本發明之精神和範圍之內,相對上述實施例進行各種更動與修改仍屬本發明所保護之技術範疇,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。
Claims (1)
- 一種南洋山蘇水萃物的用途,係應用於製備抑制革蘭氏陰性菌感染所造成之發炎的藥物,其中,該南洋山蘇水萃物係以水作為一萃取溶劑,於115~125℃之溫度、0.35~0.5Kg/cm2G之壓力下萃取一南洋山蘇樣品1.5~3小時所獲得。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106118699A TWI612966B (zh) | 2017-06-06 | 2017-06-06 | 南洋山蘇水萃物的用途 |
PCT/US2018/034863 WO2018226447A1 (en) | 2017-06-06 | 2018-05-29 | Method for inhibiting inflammation caused by gram-negative bacteria infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106118699A TWI612966B (zh) | 2017-06-06 | 2017-06-06 | 南洋山蘇水萃物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
TWI612966B true TWI612966B (zh) | 2018-02-01 |
TW201902503A TW201902503A (zh) | 2019-01-16 |
Family
ID=62014374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106118699A TWI612966B (zh) | 2017-06-06 | 2017-06-06 | 南洋山蘇水萃物的用途 |
Country Status (2)
Country | Link |
---|---|
TW (1) | TWI612966B (zh) |
WO (1) | WO2018226447A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018226447A1 (en) * | 2017-06-06 | 2018-12-13 | Jin Xin Biotechnology Co., Ltd. | Method for inhibiting inflammation caused by gram-negative bacteria infection |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520588A (ja) * | 2004-11-18 | 2008-06-19 | ビオファーマコペ デジン アンテルナショナル インク. | 植物抽出物およびその皮膚科使用法 |
AU2017218476B2 (en) * | 2016-02-12 | 2022-02-17 | University Of Ottawa | Decellularised cell wall structures from plants and fungus and use thereof as scaffold materials |
TWI605821B (zh) * | 2017-01-16 | 2017-11-21 | 景鑫生物科技股份有限公司 | 南洋山蘇水萃物的用途 |
TWI612966B (zh) * | 2017-06-06 | 2018-02-01 | 景鑫生物科技股份有限公司 | 南洋山蘇水萃物的用途 |
-
2017
- 2017-06-06 TW TW106118699A patent/TWI612966B/zh not_active IP Right Cessation
-
2018
- 2018-05-29 WO PCT/US2018/034863 patent/WO2018226447A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
Lih-Shiuh Lai et al,"Chemical compositions and some physical properties of the water and alkali-extracted mucilage from the young fronds of Asplenium australasicum (J. Sm.) Hook", Food Hydrocolloids, 2012, 26(2): 344-349. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018226447A1 (en) * | 2017-06-06 | 2018-12-13 | Jin Xin Biotechnology Co., Ltd. | Method for inhibiting inflammation caused by gram-negative bacteria infection |
Also Published As
Publication number | Publication date |
---|---|
WO2018226447A1 (en) | 2018-12-13 |
TW201902503A (zh) | 2019-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sun et al. | Evaluation of Analgesic and Anti‐Inflammatory Activities of Water Extract of Galla Chinensis In Vivo Models | |
CA2854209C (en) | Composition for the treatment of bacterial infections | |
WO2013013494A1 (zh) | 一种葱姜驱寒茶及其制备方法 | |
TWI612966B (zh) | 南洋山蘇水萃物的用途 | |
TWI595881B (zh) | 南洋山蘇水萃物的用途 | |
JP6980791B2 (ja) | 胃炎または消化性潰瘍予防または治療用組成物 | |
CN102614242A (zh) | 板蓝大青滴丸及其制备方法 | |
TWI612967B (zh) | 南洋山蘇水萃物的用途 | |
TWI612968B (zh) | 南洋山蘇水萃物的用途 | |
TWI615146B (zh) | 南洋山蘇水萃物的用途 | |
TWI611806B (zh) | 南洋山蘇水萃物的用途 | |
KR102119795B1 (ko) | 브로콜리 추출물을 포함하는 항염증 조성물 | |
TWI624264B (zh) | 南洋山蘇水萃物的用途 | |
KR20160098569A (ko) | 양주좀개수염 추출물을 함유하는 항염증 항산화 활성의 약학조성물 및 식품조성물 | |
Ramesh et al. | Phytochemical and in vitro Antimicrobial assay of Fruit extracts of Morinda tinctoria Roxb | |
CN105030954B (zh) | 一种治疗仔猪腹泻的组合物、制剂、制备方法及其应用 | |
KR20160023238A (ko) | 청고추 추출물을 유효 성분으로 포함하는 인플라마좀 매개 염증성 질환 및 인플루엔자 바이러스 감염 예방, 개선용 조성물 | |
CN103463388A (zh) | 一种治疗甲鱼疥疮病的药物组合物及其制备方法 | |
Kim et al. | Anti-gastritis and anti-oxidant effects of Chenopodium album Linne fractions and betaine | |
CN101822701A (zh) | 一种治疗畜禽痢疾、肠炎的杨树花缓释片及其制备方法 | |
CN104189070A (zh) | 一种消炎利胆片的其制备工艺 | |
CN109288914B (zh) | 鱼腥草总黄酮在制备防治病毒性肺炎的药物中的用途 | |
TW202116334A (zh) | 預防或改善胃部疾病的組成物及其用途 | |
CN101502536A (zh) | 香柏总黄酮及其制备方法与医药用途 | |
CN109419846B (zh) | 一种香薷挥发油在治疗诺如病毒感染性腹泻中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |